Literature DB >> 25030940

Comparative effectiveness research of chronic hepatitis B and C cohort study (CHeCS): improving data collection and cohort identification.

Mei Lu1, Loralee B Rupp, Anne C Moorman, Jia Li, Talan Zhang, Lois E Lamerato, Scott D Holmberg, Philip R Spradling, Eyasu H Teshale, Vinutha Vijayadeva, Joseph A Boscarino, Mark A Schmidt, David R Nerenz, Stuart C Gordon.   

Abstract

BACKGROUND AND AIMS: The Chronic Hepatitis Cohort Study (CHeCS) is a longitudinal observational study of risks and benefits of treatments and care in patients with chronic hepatitis B (HBV) and C (HCV) infection from four US health systems. We hypothesized that comparative effectiveness methods-including a centralized data management system and an adaptive approach for cohort selection-would improve cohort selection while controlling data quality and reducing the cost.
METHODS: Cohort selection and data collection were performed primarily via the electronic health record (EHR); cases were confirmed via chart abstraction. Two parallel sources fed data to a centralized data management system: direct EHR data collection with common data elements, and chart abstraction via electronic data capture. An adaptive Classification and Regression Tree (CART) identified a set of electronic variables to improve case ascertainment accuracy.
RESULTS: Over 16 million patient records were collected on 23 case report forms in 2006-2008. The vast majority of data (99.2%) were collected electronically from EHR; only 0.8% was collected via chart abstraction. Initial electronic criteria identified 12,144 chronic hepatitis patients; 10,098 were confirmed via chart abstraction with positive predictive values (PPV) 79 and 83% for HBV and HCV, respectively. CART-optimized models significantly increased PPV to 88 for HBV and 95% for HCV.
CONCLUSIONS: CHeCS is a comparative effectiveness research project that leverages electronic centralized data collection and adaptive cohort identification approaches to enhance study efficiency. The adaptive CART model significantly improved the positive predictive value of cohort identification methods.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25030940      PMCID: PMC5719869          DOI: 10.1007/s10620-014-3272-6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  14 in total

Review 1.  Maximizing the clinical utility of comparative effectiveness research.

Authors:  C A Umscheid
Journal:  Clin Pharmacol Ther       Date:  2010-10-20       Impact factor: 6.875

2.  Comparative effectiveness research: Policy context, methods development and research infrastructure.

Authors:  Sean R Tunis; Joshua Benner; Mark McClellan
Journal:  Stat Med       Date:  2010-08-30       Impact factor: 2.373

3.  GRACE principles: recognizing high-quality observational studies of comparative effectiveness.

Authors:  Nancy A Dreyer; Sebastian Schneeweiss; Barbara J McNeil; Marc L Berger; Alec M Walker; Daniel A Ollendorf; Richard E Gliklich
Journal:  Am J Manag Care       Date:  2010-06       Impact factor: 2.229

4.  Prioritizing comparative-effectiveness research--IOM recommendations.

Authors:  John K Iglehart
Journal:  N Engl J Med       Date:  2009-06-30       Impact factor: 91.245

5.  Comparative effectiveness research: guidelines for good practices are just the beginning.

Authors:  Michael L Johnson; Abhishek S Chitnis
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2011-02       Impact factor: 2.217

6.  From the bedside to the community: comparative effectiveness, health services, and implementation research.

Authors:  Catherine Rongey; Hal F Yee
Journal:  Hepatology       Date:  2011-02       Impact factor: 17.425

7.  Learning health care systems: leading through research: the 18th Annual HMO Research Network Conference, April 29-May 2, 2012, Seattle, Washington.

Authors:  Katherine M Newton; Eric B Larson
Journal:  Clin Med Res       Date:  2012-08

8.  Hepatitis C in the United States.

Authors:  Scott D Holmberg; Philip R Spradling; Anne C Moorman; Maxine M Denniston
Journal:  N Engl J Med       Date:  2013-05-16       Impact factor: 91.245

9.  Longitudinal data analysis for discrete and continuous outcomes.

Authors:  S L Zeger; K Y Liang
Journal:  Biometrics       Date:  1986-03       Impact factor: 2.571

10.  Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population.

Authors:  Stuart C Gordon; Lois E Lamerato; Loralee B Rupp; Jia Li; Scott D Holmberg; Anne C Moorman; Philip R Spradling; Eyasu H Teshale; Vinutha Vijayadeva; Joseph A Boscarino; Emily M Henkle; Nancy Oja-Tebbe; Mei Lu
Journal:  Clin Gastroenterol Hepatol       Date:  2013-10-06       Impact factor: 11.382

View more
  4 in total

1.  Changing trends in complications of chronic hepatitis C.

Authors:  Mei Lu; Jia Li; Loralee B Rupp; Yueren Zhou; Scott D Holmberg; Anne C Moorman; Philip R Spradling; Eyasu H Teshale; Joseph A Boscarino; Yihe G Daida; Mark A Schmidt; Sheri Trudeau; Stuart C Gordon
Journal:  Liver Int       Date:  2017-07-21       Impact factor: 5.828

2.  Serum Biomarkers Indicate Long-term Reduction in Liver Fibrosis in Patients With Sustained Virological Response to Treatment for HCV Infection.

Authors:  Mei Lu; Jia Li; Talan Zhang; Loralee B Rupp; Sheri Trudeau; Scott D Holmberg; Anne C Moorman; Philip R Spradling; Eyasu H Teshale; Fujie Xu; Joseph A Boscarino; Mark A Schmidt; Vinutha Vijayadeva; Stuart C Gordon
Journal:  Clin Gastroenterol Hepatol       Date:  2016-01-22       Impact factor: 11.382

Review 3.  Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection: Current Chronic Hepatitis Cohort Study Status and Review of Findings.

Authors:  Anne C Moorman; Loralee B Rupp; Stuart C Gordon; Yuna Zhong; Jian Xing; Mei Lu; Joseph A Boscarino; Mark A Schmidt; Yihe G Daida; Eyasu H Teshale; Philip R Spradling; Scott D Holmberg
Journal:  Infect Dis Clin North Am       Date:  2018-06       Impact factor: 5.982

4.  Trends in Diagnosed Chronic Hepatitis B in a US Health System Population, 2006-2015.

Authors:  Mei Lu; Yueren Zhou; Scott D Holmberg; Anne C Moorman; Philip R Spradling; Eyasu H Teshale; Joseph A Boscarino; Yihe G Daida; Mark A Schmidt; Jia Li; Loralee B Rupp; Sheri Trudeau; Stuart C Gordon
Journal:  Open Forum Infect Dis       Date:  2019-06-14       Impact factor: 3.835

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.